Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Issued (2022 - 2025)

Zentalis Pharmaceuticals has reported Shares Issued over the past 4 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Shares Issued at $5.1 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $5.4 million (up 1444.41% YoY), and the annual figure for FY2025 was $5.4 million, up 1444.41%.
  • Shares Issued for Q4 2025 was $5.1 million at Zentalis Pharmaceuticals, up from $115000.0 in the prior quarter.
  • Over the last five years, Shares Issued for ZNTL hit a ceiling of $235.3 million in Q2 2023 and a floor of -$234.1 million in Q3 2023.
  • Median Shares Issued over the past 4 years was $248000.0 (2024), compared with a mean of $18.6 million.
  • Peak annual rise in Shares Issued hit 1097.74% in 2023, while the deepest fall reached 212.59% in 2023.
  • Zentalis Pharmaceuticals' Shares Issued stood at $48.6 million in 2022, then crashed by 581.35% to -$234.1 million in 2023, then skyrocketed by 100.04% to $92000.0 in 2024, then skyrocketed by 5428.26% to $5.1 million in 2025.
  • The last three reported values for Shares Issued were $5.1 million (Q4 2025), $115000.0 (Q3 2025), and $189000.0 (Q1 2025) per Business Quant data.